Herpes Simplex Virus Treatment Market Growth Report, 2032
Herpes Simplex Virus Treatment Market Industry Report, 2024-2032

Herpes Simplex Virus Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Herpes Simplex Virus-1, Herpes simplex virus-2); By Drug; By Vaccine; By Route of Administration; By End-use; By Region; Segment Forecast, 2024 - 2032

  • Published Date:Jan-2024
  • Pages: 115
  • Format: PDF
  • Report ID: PM4333
  • Base Year: 2023
  • Historical Data: 2019 – 2022

Report Outlook

Herpes Simplex Virus Treatment Market size was valued at USD 2.26 billion in 2023. The market is anticipated to grow from USD 2.44 billion in 2024 to USD 4.66 billion by 2032, exhibiting a CAGR of 8.4% during the forecast period.

The market research report offers an in-depth analysis of the industry to support informed decision-making. It offers a meticulous breakdown of various market niches and keeps readers updated on the latest industry developments. Along with tracking the herpes simplex virus treatment market on the basis of SWOT and Porter’s Five Forces models, the research report includes graphs, tables, charts, and other pictorial representations to help readers understand the key insights and important data easily. 

Market Overview

Herpes simplex is a highly transmitted virus that mostly affects a larger population through skin-to-skin contact and saliva from infected people. It is known to last for a week to ten days but is known to infect periodically with the painful blisters. The increased risk of infection from others underscores the sustained demand for herpes simplex virus treatment. Researchers are showing interest in innovating treatments for the herpes simplex virus.

  • For instance, in May 2023, a study published in ACS publications developed a molecule that can treat lesions due to the shingles virus. It showcased significant potential to treat genital and oral herpes.

Moreover, there are ongoing concerns about the herpes simplex virus, primarily HSV-2, due to its chance of transmission through sexual contact. According to the World Health Organization, HSV-2 increases the chance of getting and spreading HIV infection. The ongoing efforts by governments and non-government organizations to curb HIV infections are anticipated to bolster the need for herpes simplex virus treatment in the global market.

Herpes Simplex Virus Treatment Market Size

To Understand More About this Research: Request a Free Sample Report

Growth Drivers

  • The rising infection rate in the world.

The increasing population at the global level is creating a need for sophisticated healthcare infrastructure along with the development of new biopharmaceutical products to cure health problems. The higher rate of transmission of the herpes simplex virus is necessitating the development of new medical products. According to the World Health Organization, around 3.7 Bn people aged below 50, which constitutes 67% of the global population, are expected to be infected by the HSV-1 infection. This trend is boosting the demand for hsv 2 treatment throughout the forecast period.

  • The rising studies exploring cell and gene therapies are driving the market growth

The emergence of gene and cell therapies has led to their utilisation for the treatment of various diseases, including cancer, cardiology, kidney-related problems, and more. This ongoing trend is showing significant opportunities for researchers to explore generative medicine to cure the herpes simplex virus. For instance, in 2022, a study published in BioRxiv focused on developing gene therapy for herpes and identified a reduction in the transmission of the virus in mice. As research activities continue to rise, there will be a chance of generating the most efficient treatment to treat herpes simplex virus.

Restraining Factors

Regulatory hurdles are likely to impede market growth.

The chance of errors in the testing of the herpes simplex virus by healthcare providers is likely to underestimate the herpes simplex tests in the marketplace. In December 2023, the Food and Drug Administration announced the potential of HSV-2 to produce false positives for genital herpes simplex infection. This can hamper the new hsv2 medication demand in the global market.

Report Segmentation

The market is primarily segmented based on type, drug, vaccine, route of administration, end-use, and region.

By Type

By Drug

By Vaccine

By Route of Administration

By End-use

By Region

  • Herpes Simplex Virus-1 (HSV-1)
  • Herpes simplex virus-2 (HSV-2)
  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Other Drugs

 

 

  • Simplirix
  • Others

 

 

  • Oral
  • Injectable
  • Topical
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Type Analysis

Herpes Simplex Virus-1 (HSV-1) segment is projected to witness the highest market growth during the forecast period.

The herpes simplex virus-1 segment is projected to witness the highest market growth during the forecasted period, mainly driven by a higher rate of infection contact with other people due to saliva. In the U.S., around half of the population is infected by HSV-1, while 30% of people get infected by HSV-2. This trend is contributing to the HSV-1 segment herpes simplex virus treatment market share.

By Drug Analysis

The Valacyclovir segment accounted for the largest market share in 2023

The valacyclovir segment held the highest market share in 2023 and is expected to maintain this position throughout the entire forecast period. Its effective antiviral medicine is mostly used to get relief from herpes viruses, including cold sores, shingles, and more. One of the advantages of valacyclovir is that it can offer a longer period of action. The acyclovir segment is expected to grow at the fastest rate over the next few years on account of its capability to lessen the length of the outbreak of the herpes simplex virus and its severity among infected people.

By Route of Administration Analysis

The oral segment registered the dominant share in the global market analysis in 2023.

The oral segment held the largest share in the herpes simplex virus treatment market over other routes of administration and is likely to retain its market position during the forecast period. This can be related to the rising incidence of oral ulcers among the population due to herpes simplex virus.

By End-use Analysis

The retail pharmacy segment registered the largest market growth over other end-use segments in 2023.

The retail pharmacy segment witnessed a larger share among other end-use segments and is expected to continue its growth trajectory in the coming years. This can be attributable to the increased accessibility of products to treat sores from the herpes simplex virus in the marketplace. The online pharmacy segment is expected to witness significant growth in the coming years, driven by the rising prevalence of telemedicine in the marketplace after the COVID-19 outbreak. 

Regional Insights

North America region registered the largest share of the global market analysis in 2023

The North American region dominated the global market. Region’s dominance is due to the rising number of people infected with the herpes simplex virus. Around 50 to 60 percent of adults in the U.S. suffer from oral herpes generated by HSV-1, and out of a total of six, one individual lives with genital herpes due to HSV-1 or HSV-2.

The Asia Pacific region will grow at a rapid pace. Due to the presence of countries with a higher population, the higher rate of virus transmission through the saliva of infected persons is likely to stimulate the need for herpes simplex virus treatment.

Key Market Players & Competitive Insights

Strategic partnerships to drive the competition

The herpes simplex virus treatment market is characterized by the presence of several players and an increasing number of new players in the development of feasible treatment options for the herpes simplex virus. The increasing strategic collaborations, mergers and acquisitions, and product innovations are driving the expansion of the herpes simplex virus treatment market. For instance, in 2022, Moderna expanded its product portfolio with the addition of vaccines for shingles, HSV, and cancer.

Some of the major players operating in the global market landscape include:

  • Apotex Inc.
  • Carlsbad Tech
  • Emcure Pharmaceuticals Ltd.
  • Fresenius Kabi AG
  • GSK plc
  • Glenmark Pharmaceuticals Inc.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceuticals Industries Ltd.
  • Viatris, Inc.

Recent Developments in the Industry

  • In October 2023, BioNTech developed a vaccine for the genital herpes simplex virus (HSV-2) and potentially HSV-1. It is undergoing clinical trials to get approval from the U.S. FDA.

Report Coverage

The herpes simplex virus treatment market report emphasizes key regions across the globe to provide a better understanding of the product to the users. Also, the report provides market insights into recent developments and trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers an in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.

The report provides a detailed analysis of the market while focusing on various key aspects such as competitive analysis, type, drug, vaccine, route administration, end-use, and their futuristic growth opportunities.

Herpes Simplex Virus Treatment Market Report Scope

Report Attributes

Details

Market size value in 2024

USD 2.44 billion

Revenue Forecast in 2032

USD 4.66 billion

CAGR

8.4% from 2024 – 2032

Base year

2023

Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments Covered

  • By Type
  • By Drug
  • By Vaccine
  • By Route of Administration
  • By End-use
  • By Region

Regional scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape

  • Herpes Simplex Virus Treatment Market Share Analysis (2023)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format

  • PDF + Excel

Customization

Report customization as per your requirements with respect to countries, regions, and segmentation.

Gain profound insights into the 2024 herpes simplex virus treatment market with meticulously compiled statistics on market share, size, and revenue growth rate by Polaris Market Research Industry Reports. This thorough analysis not only provides a glimpse into historical trends but also unfolds a roadmap with a market forecast extending to 2032. Immerse yourself in the comprehensive nature of this industry analysis through a complimentary PDF download of the sample report.

Browse Our Top Selling Reports

Cognitive Radio Market Size, Share 2024 Research Report
Child Care Services Market Size, Share 2024 Research Report
Dog Vaccine Market Size, Share 2024 Research Report
High Frequency Trading Servers Market Size, Share 2024 Research Report
Pigment Dispersion Market Size, Share 2024 Research Report

FAQ's

The global herpes simplex virus treatment market size is expected to reach USD 4.66 billion by 2032

Key players in the market are Apotex Inc., Carlsbad Tech, Emcure Pharmaceuticals Ltd., Fresenius Kabi AG, GSK plc

North American contribute notably towards the global Herpes Simplex Virus Treatment Market

Herpes Simplex Virus Treatment Market exhibiting a CAGR of 8.4% during the forecast period.

The Herpes Simplex Virus Treatment Market report covering key segments are type, drug, vaccine, route of administration, end-use, and region.